Insulin use and new diabetes after acceptance for bariatric surgery: comparison of outcomes after completion of surgery or withdrawal from the program.


Journal

BMJ open diabetes research & care
ISSN: 2052-4897
Titre abrégé: BMJ Open Diabetes Res Care
Pays: England
ID NLM: 101641391

Informations de publication

Date de publication:
12 2020
Historique:
received: 15 08 2020
revised: 16 10 2020
accepted: 26 10 2020
entrez: 3 12 2020
pubmed: 4 12 2020
medline: 22 6 2021
Statut: ppublish

Résumé

In people accepted onto a bariatric surgery program we compared diabetes-related outcomes in those who completed surgery with those who withdrew before having surgery-examining rates of insulin use in people with type 2 diabetes (T2D), and rates of incident diabetes in people without pre-existing T2D. 771 people were accepted onto the program. 463 people (60%) had T2D at referral, of which 48% completed surgery and 52% withdrew. Of 308 people without T2D at referral, 49% completed surgery, and 51% withdrew. Rates of insulin use and incident diabetes were compared by Kaplan-Meier analyses. Among those with pre-existing T2D, we examined rates of remission and relapse after surgery. People without T2D who withdrew from the program had higher mean body mass index and glycated hemoglobin levels than those completing surgery (p<0.005). The rate of incident diabetes at 5 years was 19% in those who withdrew versus 0% in those completing surgery (p<0.001). 30% of people with T2D were taking insulin at referral and all stopped insulin after surgery. During follow-up, the rate of insulin (re)introduction was lower in those who completed surgery (8% vs 26% at 5 years, p<0.001). Of those with T2D who completed surgery, 80% had remission, but 34% had relapsed by 5 years. Diabetes relapse was associated with less weight loss after surgery, a longer duration of T2D and previous insulin use. Despite a high relapse rate, people with T2D who completed surgery had lower insulin use at 5 years than those withdrawing from the program. In people without T2D, bariatric surgery prevented incident diabetes. People without T2D who withdrew from the program were at greater risk of diabetes, suggesting those who could benefit the most in terms of T2D prevention are not completing bariatric surgery.

Identifiants

pubmed: 33268449
pii: 8/2/e001837
doi: 10.1136/bmjdrc-2020-001837
pmc: PMC7712440
pii:
doi:

Substances chimiques

Insulin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Diabetologia. 2017 Oct;60(10):1892-1902
pubmed: 28733906
Diabet Med. 2018 Mar;35(3):360-367
pubmed: 29055156
Curr Opin Gastroenterol. 2016 Nov;32(6):481-486
pubmed: 27607341
J Am Coll Surg. 2020 Jan;230(1):7-16
pubmed: 31672669
N Engl J Med. 2017 Feb 16;376(7):641-651
pubmed: 28199805
JAMA Surg. 2020 May 1;155(5):e200087
pubmed: 32129809
Obes Surg. 2014 Jan;24(1):134-40
pubmed: 24122658
Lancet. 2015 Sep 5;386(9997):964-73
pubmed: 26369473
Lancet Diabetes Endocrinol. 2014 Dec;2(12):963-8
pubmed: 25466723
Obes Surg. 2018 Aug;28(8):2500-2507
pubmed: 29525936
PLoS Med. 2015 Dec 22;12(12):e1001925
pubmed: 26694640
Surg Obes Relat Dis. 2007 Sep-Oct;3(5):531-5; discussion 535-6
pubmed: 17903773
Obes Surg. 2019 Mar;29(3):796-804
pubmed: 30467708
Diabetes Care. 2015 Apr;38(4):659-64
pubmed: 25573879
Obes Surg. 2020 Oct;30(10):3955-3960
pubmed: 32535782
N Engl J Med. 2012 Aug 23;367(8):695-704
pubmed: 22913680
Can J Diabetes. 2017 Aug;41(4):401-406
pubmed: 28457649
N Z Med J. 2012 Sep 21;125(1362):70-80
pubmed: 23178606
Obes Surg. 2017 Jan;27(1):2-21
pubmed: 27957699
Diabetologia. 2018 Feb;61(2):257-264
pubmed: 29224190
Obes Surg. 2017 Oct;27(10):2724-2732
pubmed: 28801703
Diabetes Care. 2020 Mar;43(3):534-540
pubmed: 31974105
BMJ Open. 2014 Apr 28;4(4):e003975
pubmed: 24776708
Diabetes Res Clin Pract. 2019 Feb;148:119-129
pubmed: 30633935
Obes Surg. 2013 Jan;23(1):93-102
pubmed: 23161525
N Engl J Med. 2008 Oct 9;359(15):1577-89
pubmed: 18784090

Auteurs

Jessica H Lee (JH)

Auckland Diabetes Centre, Auckland City Hospital, Auckland, Aotearoa-New Zealand drjessica.lee2@gmail.com.

Rebekah Jaung (R)

Faculty of Medical and Health Sciences, The University of Auckland, Auckland, Aotearoa-New Zealand.

Grant Beban (G)

Hepatobiliary and Upper GI Unit, Department of General Surgery, Auckland City Hospital, Auckland, Aotearoa-New Zealand.

Nicholas Evennett (N)

Hepatobiliary and Upper GI Unit, Department of General Surgery, Auckland City Hospital, Auckland, Aotearoa-New Zealand.

Tim Cundy (T)

Auckland Diabetes Centre, Auckland City Hospital, Auckland, Aotearoa-New Zealand.
Faculty of Medical and Health Sciences, The University of Auckland, Auckland, Aotearoa-New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH